Prehospital Analgesia INtervention Trial (PAIN)

Purpose

The Prehospital Analgesia INtervention trial (PAIN) is a proposed 4 year (3-year enrollment) multicenter, prehospital, randomized, double-blind, clinical trial that will enroll approximately 994 patients at select LITES Network sites. The objective is to perform a prospective, interventional, randomized trial among prehospital trauma patients with compensated shock (SI≥0.9 or HR ≥115) and an indication for pain management, comparing patient centered outcomes following prehospital administration of ketamine hydrochloride versus fentanyl citrate.

Condition

  • Traumatic Injury

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Transport after injury to a participating PAIN Trauma center - 2. Patient with compensated shock as defined by Shock Index (SI) ≥0.9 or Heart Rate (HR) ≥115. - Intravenous pain medication indicated (CPOT≥2, NRS≥5) prior to arrival at the trauma center

Exclusion Criteria

  • No IV access - Age <18 years - Females <50 years of age - SBP>180 mmHg at time of enrollment - Advanced airway management prior to first dose administration - Known allergy to fentanyl citrate or ketamine hydrochloride - Known prisoner - Objection to study voiced by subject or family member at scene - Pain treatment contraindicated by local protocol - Wearing a "NO PAIN STUDY" bracelet

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Intervention Model Description
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Care Provider)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Ketamine Hydrochloride
2 blinded doses 2.5mg/ml ketamine hydrochloride in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after approximately 15 minutes if the subject has a qualifying pain score, there are no contraindications to pain medication per local protocol, and no exclusion criteria have been met.
  • Drug: Ketamine Hydrochloride
    ketamine hydrochloride 2.5mg/ml packaged in pre-filled syringe
Active Comparator
Fentanyl Citrate
2 blinded doses 10mcg/ml in separately sealed pre-filled syringes Subjects will be administered the first dose over approximately 2 minutes via slow IV push. Pain assessment following administration will be obtained and recorded every 15 minutes. Redosing may occur after approximately 15 minutes if the subject has a qualifying pain score, there are no contraindications to pain medication per local protocol, and no exclusion criteria have been met.
  • Drug: Fentanyl Citrate
    fentanyl citrate 10mcg/ml packaged in pre-filled syringe

Recruiting Locations

University of California, San Diego
San Diego, California 92103
Contact:
Laura Haines, MD
619-543-7200
lhaines@health.ucsd.edu

Zuckerberg San Francisco General Hospital
San Francisco, California 94110
Contact:
Lucy Kornblith, MD
415-609-6924
Lucy.Kornblith@ucsf.edu

Cooper University Health Care
Camden, New Jersey 08103
Contact:
Tanya Egodage
856-342-3341
egodage-tanya@cooperhealth.edu

Atrium Health and Carolinas Medical Center
Charlotte, North Carolina 28203
Contact:
Addison May, MD
704 446-2504
addison.may@atriumhealth.org

University of Cincinnati
Cincinnati, Ohio 45267
Contact:
Jason McMullan, MD
513-675-3072
Jason.McMullan@uc.edu

Allegheny Health Network (AHN) Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Philip Nawrocki, MD
4124876590
philip.nawrocki@ahn.org

University of Pittsburgh
Pittsburgh, Pennsylvania 15213
Contact:
Jason Sperry, MD
412-647-3065
sperryjl@upmc.edu

Guthrie Robert Packer Hospital
Sayre, Pennsylvania 18840
Contact:
Jon Rittenberger, MD
570-887-4318
Jon.Rittenberger@guthrie.org

University of Utah
Salt Lake City, Utah 84132
Contact:
Scott Youngquist, MD
scott.youngquist@hsc.utah.edu

The University of Vermont Larner College of Medicine
Burlington, Vermont 05405
Contact:
Daniel Wolfson, MD, FACEP, FAEMS
802-847-2434
daniel.wolfson@uvmhealth.org

More Details

NCT ID
NCT05437575
Status
Recruiting
Sponsor
Jason Sperry

Study Contact

Jason Sperry, MD
412-802-8270
sperryjl@upmc.edu